Efficacy and Safety of Xialiqi for the Treatment of Benign Prostatic Hyperplasia in a Randomized Trial
We looked at the safety and efficacy of Xialiqi capsules for the treatment of benign enlargement of the prostate gland in a large Chinese population. We found that Xialiqi provides an early improvement in urinary symptoms and prostate enlargement in men with moderate symptoms relating to an enlarged prostate.
Authors
- Dong Chen (ORCID: https://orcid.org/0000-0002-7692-7529)
- Feiya Yang
- Chao Yang (ORCID: https://orcid.org/0000-0001-9962-5008)
- Chang Yin Liang (ORCID: https://orcid.org/0000-0003-2317-1323)
- Wei Li (ORCID: https://orcid.org/0000-0002-7973-6242)
- Zhiping Wang (ORCID: https://orcid.org/0000-0002-8140-591X)
- Zhong Wang
- Xin Wang (ORCID: https://orcid.org/0000-0002-9679-7426)
- Jianwen Wang (ORCID: https://orcid.org/0000-0003-2227-1867)
- Jianxin Lü (ORCID: https://orcid.org/0000-0002-8925-9654)
- Hua Lin
- Hao Ping
Institutions
- Hebei Medical University (CN)
- Beijing Tongren Hospital (CN)
- Shanghai Jiao Tong University (CN)
- Capital Medical University (CN)
- Anhui Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Beijing Chao-Yang Hospital, Capital Medical University (CN)
- Renji Hospital (CN)
- National Cancer Center (US)
- Shanghai Ninth People's Hospital (CN)
- Second Hospital of Hebei Medical University (CN)
- Shanxi Provincial Cancer Hospital (CN)
- Lanzhou University Second Hospital (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
- Guang’anmen Hospital (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- European Urology Open Science
- Published
- 2025-10-25
- DOI
- https://doi.org/10.1016/j.euros.2025.10.006
- Primary Topic
- Urinary Bladder and Prostate Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00